Avistone
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing targeted small molecule and antibody therapies for oncology, particularly lung cancer.
Oncology
Technology Platform
A platform for the discovery and development of selective small molecule kinase inhibitors and therapeutic antibodies targeting validated oncology pathways.
Opportunities
Significant market opportunity in China for novel, targeted oncology therapies with improved safety and efficacy profiles.
Risk Factors
Clinical and regulatory risks associated with late-stage development, plus intense competition in the core indication.
Competitive Landscape
Operates in the highly competitive NSCLC targeted therapy space, competing with global leaders like AstraZeneca and domestic players such as Jiangsu Hengrui.